Dr. Herbert L. Bonkovsky, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (1967)
- Years since graduation
- 59
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 66
Licensed in Connecticut since 1999, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1967Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NC license 2008-00082 · CT license 037512 (first issued 1999; inactive)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Carolina Baptist Hospital Winston-Salem, NC
Medical groups
- Wake Forest University Health Sciences (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 80
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 58 | 43 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carvedilol Other prescribers in Winston Salem, NC | 52 |
| Ursodiol Other prescribers in Winston Salem, NC | 50 |
| Furosemide Other prescribers in Winston Salem, NC | 36 |
| Spironolactone Other prescribers in Winston Salem, NC | 31 |
| Xifaxan (rifaximin) Other prescribers in Winston Salem, NC | 31 |
| Lactulose Other prescribers in Winston Salem, NC | 20 |
| Eliquis (apixaban) Other prescribers in Winston Salem, NC | 17 |
| Mycophenolate Mofetil Other prescribers in Winston Salem, NC | 15 |
| Pantoprazole Sodium Other prescribers in Winston Salem, NC | 14 |
| Vemlidy (tenofovir alafenamide) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $511 in total to this clinician.
| Merck Sharp & Dohme LLC | $375 |
|---|---|
| Cook Medical LLC | $80.70 |
| Alnylam Pharmaceuticals Inc. | $38.49 |
| Novo Nordisk Inc | $16.86 |
| Consulting Fee | $375 |
|---|---|
| Food and Beverage | $136 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a research engagement. | $375 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $183,862 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Tanabe Pharma America, Inc. - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria
Tanabe Pharma America, Inc. - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences, Inc. - ELEVATE: A global observational longitudinal propsective registry of patients with acute hepatic prphyria (AHP).
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.